SSY Group Gains China Approval for New Drugs

  Published 1 year ago

SSY Group Ltd. received Chinese regulatory approval for two new pharmaceutical products: Dronedarone Hydrochloride Tablets (antiarrhythmic) and Gabexate Mesylate for Injection (pancreatitis treatment). This marks a significant advancement for the company.

  • Approval for antiarrhythmic drug, Dronedarone.
  • Gabexate Mesylate approved for pancreatitis.
  • Positive step for SSY Group's development.

You might like these

Hero MotoCorp July Sales Surge

India Shelter Q1 Profit Up 44%

Nifty Realty Slips Nearly 1%, Trails Market

CEAT Q1 Margins Fall, Expansion Planned

HUL Jumps 4.6% on New CEO News

Nilkamal Shares Slide 5% on Profit Drop

Northern Arc Q1 Profit Drops 15%

News that matters the most ⚡